No. Treat a certificate of analysis as one document addressing specified material or tests—not as an overall approval of the finished product, facility or legal route. FDA’s statutory comparison identifies a valid certificate of analysis as one of the bulk-substance conditions, alongside other requirements. (fda.gov)
Proposed quality-review questions:
- Does the certificate cover raw ingredient or finished preparation?
- Does its lot identifier match the supplied material?
- Which laboratory performed which tests, and when?
- What methods, acceptance criteria and limitations apply?
- What information addresses finished-product strength, sterility and other relevant attributes?
- What supports the assigned storage conditions and beyond-use period?
- Who reviews deviations and authorizes release?
Do not turn this checklist into an assertion that every supplier must publish identical testing records. Have a qualified quality professional assess what evidence is appropriate to the pathway and preparation.
Independent legal check remains necessary: testing cannot establish a statutory permission that the proposed arrangement otherwise lacks.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding